sold 2/3 of my position a few weeks ago to by EXAS, pretty happy with that decision. I would have sold it all, but I have covered calls still active, the only ARNA investment making a profit. Stock is a real POS, sorry I still own any and sorry I did not listen to friends that told me to sell (not referring to the liars and jokers that post here). Until Jack goes, ARNA will not go higher.
NVS has one undisclosed and 2 disclosed. Sanofi has 4 total, only one undisclosed, AMGN has 2 and 2, LLY has one, Bayer has one, the BT drug looks very interesting + Kadcyla + something like $800MM on NOL's + cash + patents, technology...$1BB is a bad joke.
Shorts better hope not, that stock is highly valued, even coveted by investors. Look at the multiples! I may just have to hold EXAS until it's acquired.
Hard to believe IMGN is valued at $1BB with such a large pipeline, technology/platform, Kadcyla, etc. There are many other companies with much smaller pipelines valued at, or above IMGN (SGEN is at 5x). IMGN is trading at a discount based on weak executive management and a history of clinical disappointments, except for Kadcyla, which so far has been a commercial disappointment. At the current valuation, someone with drug development and marketing skills could and should acquire IMGN. At 2x the current price the stock is a bargain thanks to DJ and co.
I am ready to try the test, but Aetna never called me back. Will have to call them again.
Looks like some analysts are not updating their price targets, models, reports on EXAS. The quality of coverage seems to be lacking and maybe that spells opportunity, under-followed, under-investment, and institutional buying needed. Of course that leads to more short covering required, a viscous cycle leading to higher prices.
Where and when will the madness end? No signs just yet with a close on high and up in the AH. Not to cheer, just trying to figure out at what price/valuation EXAS goes from fair value to overvalued due to short's being forced to cover. Anyone?
Curious to see what the rev projections, earnings estimates and price targets. I guess we can get some of that info from the yahoo analyst estimates tab.
I don't see a surge coming until the pipeline moves forward, if that should ever happen. Junius must know something if he's holding some of those free shares this time. He only acts in his own personal financial interest. For now, IMGN can't break $12.20's and is down over 30% in a strong market...not very impressive!
It's been a good month. The M&A deal yesterday got Cramer all cranked up on mid-size/deal size biotech again, so he's sure to be pumping all week. Shorts are running like #$%$ a roaches in the daylight. For the spelling police, that was an intentional misspelling. Tony Montana.
unless they get some help in the form of bad news, shorts have no way of buying 25MM shares without causing a major price increase. They are trapped. Ring ring, mr. shorty we are calling your shares in, you must buy and cover within 3 days...
Looks like the Sept 27 calls and Jan 25's were both new buys, OI increased for both. $4 in 25 days, Hmmm. I noticed Cramer is planning to pump up biotech all week, not good news for the bio-shorts.
Carol.Hausner is the person responsible, or irresponsible depending on your opinion. Apparently she's too busy assisting the business development department with their 3-year vacations. Perhaps she could train her assistant to do internet updating. She may be too busy fending off angry shareholders who are tired of losing money.